Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Tim Moderer, Ioana Puşcalău-Gîrţu, Christian Haupt, Julian Baur, Armando Rodríguez-Alfonso, Sebastian Wiese, Christoph Q. Schmidt, Miroslav Malešević, Wolf-Georg Forssmann, Ludger Ständker & Marcus Fändrich. (2023) Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis. Amyloid 30:4, pages 424-433.
Read now
Read now
Masashi Narazaki & Tadamitsu Kishimoto. (2022) Current status and prospects of IL-6–targeting therapy. Expert Review of Clinical Pharmacology 15:5, pages 575-592.
Read now
Read now
Reina Tsuda, Koichiro Shinoda, Ryuichi Ushijima, Makiko Nakamura, Nagaaki Katoh, Johji Imura & Kazuyuki Tobe. (2021) A case of wild-type transthyretin cardiac amyloidosis with rheumatoid arthritis. Modern Rheumatology Case Reports 5:2, pages 206-213.
Read now
Read now
H Shimagami & Y Katada. (2019) Successful treatment with tocilizumab for massive ascites due to secondary amyloidosis complicating rheumatoid arthritis: a case report. Scandinavian Journal of Rheumatology 48:6, pages 505-506.
Read now
Read now
Yasuaki Okuda, Toshiyuki Yamada, Mitsuharu Ueda & Yukio Ando. (2019) Nationwide survey of 199 patients with reactive amyloid a amyloidosis in Japan. Amyloid 26:sup1, pages 129-129.
Read now
Read now
Yasuaki Okuda. (2019) AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Modern Rheumatology 29:2, pages 268-274.
Read now
Read now
Naoya Toriu, Masayuki Yamanouchi, Rikako Hiramatsu, Noriko Hayami, Junichi Hoshino, Akinari Sekine, Masahiro Kawada, Eiko Hasegawa, Tatsuya Suwabe, Keiichi Sumida, Naoki Sawa, Kenmei Takaichi, Motoko Yanagita & Yoshifumi Ubara. (2019) Tocilizumab prevents renal function of a patient with diabetic kidney disease: case report. Modern Rheumatology Case Reports 3:1, pages 53-56.
Read now
Read now
Tomohiro Koga, Kiyoshi Migita & Atsushi Kawakami. (2016) Biologic therapy in familial Mediterranean fever. Modern Rheumatology 26:5, pages 637-641.
Read now
Read now
Alice Courties, Gilles Grateau, Peggy Philippe, René-Marc Flipo, Leonardo Astudillo, Bérengère Aubry-Rozier, Isabelle Fabreguet, Wafki Fahd, Olivier Fain, Pascal Guggenbuhl, Eric Hachulla, Thomas Papo, Christophe Richez, Jean Sibilia, Jacques Morel, Francis Berenbaum & Jérémie Sellam. (2015) AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid 22:2, pages 84-92.
Read now
Read now
Soken-Nakazawa J Song & Kazuyuki Yoshizaki. (2015) Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology 11:2, pages 307-316.
Read now
Read now
Esin Sogutlu Sari, Alper Yazıcı, Hasan Aksit, Arzu Yay, Gözde Sahin, Onur Yildiz, Sıtkı Samet Ermis, Kamil Seyrek & Betul Yalcin. (2015) Inhibitory Effect of Sub-conjunctival Tocilizumab on Alkali Burn Induced Corneal Neovascularization in Rats. Current Eye Research 40:1, pages 48-55.
Read now
Read now
Toshio Tanaka, Yoshihiro Hishitani & Atsushi Ogata. (2014) Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics: Targets and Therapy 8, pages 141-153.
Read now
Read now
Articles from other publishers (36)
Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku, Norshalena Shakespear, Yuichiro Kiko, Kentaro Kikuchi, Yuya Sumichika, Kenji Saito, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Eiji Suzuki, Hiroshi Watanabe, Hiromasa Ohira & Kiyoshi Migita. (2023) Case report: Rapid development of amyloid A amyloidosis in temporal arteritis with SAA1.3 allele; An unusual case of intestinal amyloidosis secondary to temporal arteritis. Frontiers in Immunology 14.
Crossref
Crossref
Sabine Karam, Mohamad Haidous, Virginie Royal & Nelson Leung. (2023) Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney International 103:3, pages 473-484.
Crossref
Crossref
A. S. Avdeeva. (2022) Inflammatory markers in rheumatic diseases. Rheumatology Science and Practice 60:6, pages 561-569.
Crossref
Crossref
Guzin Karatemiz, Sinem Nihal Esatoglu, Mert Gurcan, Yesim Ozguler, Sebahattin Yurdakul, Vedat Hamuryudan, Izzet Fresko, Melike Melikoglu, Emire Seyahi, Serdal Ugurlu, Huri Ozdogan, Hasan Yazici & Gulen Hatemi. (2023) Frequency of AA amyloidosis has decreased in Behçet’s syndrome: a retrospective study with long-term follow-up and a systematic review. Rheumatology 62:1, pages 9-18.
Crossref
Crossref
Kastriot Kastrati, Daniel Aletaha, Gerd R Burmester, Eva Chwala, Christian Dejaco, Maxime Dougados, Iain B McInnes, Angelo Ravelli, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Desirée van der Heijde, Marieke J H Voshaar, Kevin Winthrop, Josef S Smolen & Andreas Kerschbaumer. (2022) A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 8:2, pages e002359.
Crossref
Crossref
Jordan Thorne, David Clark, Laurette Geldenhuys, Keigan More, Amanda Vinson & Karthik Tennankore. (2022) Serum Amyloid A Protein–Associated Kidney Disease: Presentation, Diagnosis, and Management. Kidney Medicine 4:8, pages 100504.
Crossref
Crossref
Satoshi Yamashita, Masao Saotome, Takeji Saitoh, Noriyoshi Ogawa & Yuichiro Maekawa. (2022) Long-term effect of tocilizumab on left ventricular hypertrophy and systolic dysfunction in AA amyloidosis with rheumatoid arthritis. Journal of Cardiology Cases 25:3, pages 177-181.
Crossref
Crossref
Iva Sorić Hosman, Ivanka Kos & Lovro Lamot. (2021) Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker. Frontiers in Immunology 11.
Crossref
Crossref
Ju-Yang Jung, Young-Bae Kim, Ji-won Kim, Chang-Hee Suh & Hyoun-Ah Kim. (2021) Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy. Medicine 100:32, pages e26843.
Crossref
Crossref
J. Beimler. (2021) Renale AmyloidosenRenal amyloidoses. Der Nephrologe 16:1, pages 47-56.
Crossref
Crossref
D. G. Rumyantseva, E. M. Agafonova, S. O. Krasnenko, A. S. Starkova, M. M. Urumova & Sh. Erdes. (2020) Clinical features of ankylosing spondylitis in patients with secondary AA amyloidosis. Modern Rheumatology Journal 14:3, pages 45-49.
Crossref
Crossref
Eiji Suzuki, Takashi Kanno, Ryoma Oda, Ryoichiro Kobashi, Hidemichi Imamura, Hajime Odajima, Makiko Yashiro Furuya & Kiyoshi Migita. (2020) Effectiveness of tocilizumab for Behcet disease complicated by amyloidosis in the intestinal tract. Medicine: Case Reports and Study Protocols 1:2, pages e0022.
Crossref
Crossref
Ayush Gupta, Narendra Kumar Bagri, Saroj Kumar Tripathy, Adarsh Barwad, Ravi Hari Phulware & Pankaj Hari. (2019) Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis. Rheumatology International 40:1, pages 153-159.
Crossref
Crossref
Feng-Xiang Qi, Ying Zhang, Ying-Lan Ji & Yong Jiang. (2019) Gastrointestinal manifestations of amyloidosis. World Chinese Journal of Digestology 27:4, pages 260-266.
Crossref
Crossref
Tatsuo Fujiwara, Kyoko Katakura & Hiromasa Ohira. 2019. Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases. Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases
97
121
.
Yasuaki Okuda, Toshiyuki Yamada, Mitsuharu Ueda & Yukio Ando. (2018) First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. Internal Medicine 57:23, pages 3351-3355.
Crossref
Crossref
Andrea Rubbert-Roth, Daniel E. Furst, Jan Michael Nebesky, Angela Jin & Erhan Berber. (2018) A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. Rheumatology and Therapy 5:1, pages 21-42.
Crossref
Crossref
Raghav Bansal, Umer Syed, Jacob Walfish, Joshua Aron & Aaron Walfish. (2018) Small Bowel Amyloidosis. Current Gastroenterology Reports 20:3.
Crossref
Crossref
Masahide Yazaki, Tsuneaki Yoshinaga, Yoshiki Sekijima, Fuyuki Kametani & Nobuo Okumura. (2018) Hereditary Fibrinogen Aα-Chain Amyloidosis in Asia: Clinical and Molecular Characteristics. International Journal of Molecular Sciences 19:1, pages 320.
Crossref
Crossref
Akira Yamagata, Takahiro Uchida, Yuji Yamada, Takashi Nakanishi, Kazue Nagai, Toshihiko Imakiire, Naoki Oshima & Hiroo Kumagai. (2017) Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: a case report. BMC Nephrology 18:1.
Crossref
Crossref
Songkiat Chantarogh, Soamarat Vilaiyuk, Thipwimol Tim-Aroon & Suchin Worawichawong. (2017) Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. BMC Nephrology 18:1.
Crossref
Crossref
Sinem Nihal Esatoglu, Gulen Hatemi, Serdal Ugurlu, Aycan Gokturk, Koray Tascilar & Huri Ozdogan. (2017) Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy. Medicine 96:34, pages e7859.
Crossref
Crossref
Sun Ae Han, Young Min Yoon, Wan Soo Lee, Yun Sung Kim, Byung Chul Shin, Jong Hoon Chung & Hyun Lee Kim. (2016) Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumor necrosis factor α inhibitor therapy. The Korean Journal of Internal Medicine 31:3, pages 601-604.
Crossref
Crossref
N. Blank, U. Hegenbart & S. Schönland. (2016) Ursachen und Therapie der systemischen AA-AmyloidoseCauses and treatment of systemic amyloidosis. Zeitschrift für Rheumatologie 75:2, pages 141-150.
Crossref
Crossref
Kazuhiro Yokota, Dai Kishida, Hidekazu Kayano, Masahide Yazaki, Yuki Shimada, Yuji Akiyama & Toshihide Mimura. (2016) A Case of Abdominal Aortic Retroperitoneal and Mesenteric Amyloid Light Chain Amyloidoma. Case Reports in Rheumatology 2016, pages 1-5.
Crossref
Crossref
Daniella M. Schwartz, Michael Bonelli, Massimo Gadina & John J. O'Shea. (2015) Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nature Reviews Rheumatology 12:1, pages 25-36.
Crossref
Crossref
Tadahiko Tamura, Shinobu Tamura, Hironori Tanaka, Yuko Ohagi, Fumitaka Taniguchi, Hirofumi Yamanishi, Toshihisa Kohara, Ritsuko Kimura, Toshio Kurihara, Takashi Ozaki, Yoshio Nakano & Tokuzo Fujimoto. (2015) Tocilizumab for intestinal amyloidosis complicated by multi-centric Castleman's disease. Clinics and Research in Hepatology and Gastroenterology 39:6, pages e79-e81.
Crossref
Crossref
Tetsuo Kobayashi, Satoshi Ito, Daisuke Kobayashi, Anri Kojima, Atsushi Shimada, Ichiei Narita, Akira Murasawa, Kiyoshi Nakazono & Hiromasa Yoshie. (2015) Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors. Clinical and Experimental Dental Research 1:2, pages 63-73.
Crossref
Crossref
S.M. Weiner & R. Bergner. (2015) Dosierung und Toxizität von Antirheumatika bei NiereninsuffizienzDosage and toxicity of antirheumatic drugs in renal insufficiency. Zeitschrift für Rheumatologie 74:4, pages 300-309.
Crossref
Crossref
Alexandre Karras, Nicolas Champtiaux, Frédéric Lioté & Eric Thervet. (2015) Atteintes rénales dans les spondyloarthrites. Revue du Rhumatisme Monographies 82:1, pages 22-26.
Crossref
Crossref
Gunilla T. WestermarkMarcus FändrichPer Westermark. (2015) AA Amyloidosis: Pathogenesis and Targeted Therapy. Annual Review of Pathology: Mechanisms of Disease 10:1, pages 321-344.
Crossref
Crossref
Yukio Ando. (2015) Amyloidosis and neurological disorders: Treatable amyloidosis. Rinsho Shinkeigaku 55:11, pages 797-803.
Crossref
Crossref
Shunsuke Yamada, Akihiro Tsuchimoto, Yoshiki Kaizu, Masatomo Taniguchi, Kosuke Masutani, Hiroshi Tsukamoto, Hiroaki Ooboshi, Kazuhiko Tsuruya & Takanari Kitazono. (2014) Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis. CEN Case Reports 3:2, pages 237-243.
Crossref
Crossref
M Mesquida, A Leszczynska, V Llorenç & A Adán. (2014) Interleukin-6 blockade in ocular inflammatory diseases. Clinical and Experimental Immunology 176:3, pages 301-309.
Crossref
Crossref
M. A. Khalighi, W. Dean Wallace & M. F. Palma-Diaz. (2014) Amyloid nephropathy. Clinical Kidney Journal 7:2, pages 97-106.
Crossref
Crossref
Ori Elkayam, Nizar Jiries, Zvi Dranitzki, Shay Kivity, Merav Lidar, Ofer Levy, Jacob Ablin, Mahmoud Abu-Shakra, Hagit Savargyl-Maman, Hagit Padova, Dan Caspi & Itzhak Rosner. (2014) Tocilizumab in Adult-onset Still’s Disease: the Israeli Experience. The Journal of Rheumatology 41:2, pages 244-247.
Crossref
Crossref